Cardio3 BioSciences appoints Dr Atta Behfar

pharmafile | July 29, 2010 | Appointment | Research and Development |  Cardio3, appointment, research and development 

Belgium biotech company Cardio3 BioSciences has appointed Dr Atta Behfar as director for advanced research.

He will spend a year at the company, joining its research and development operations while on assignment from US healthcare institute the Mayo Clinic.

Dr Behfar was a member of the Mayo Clinic’s clinician investigator programme in cardiology and played a key role in the research underlying Cardio3 BioSciences’ lead product, C-Cure, a stem cell treatment for heart failure.

He said: “It is a very exciting time for Cardio3 BioSciences with C-Cure having shown encouraging early results in a clinical setting. I look forward to working with the in-house team as they further advance the product from being a scientific concept towards becoming a therapy that could potentially treat one of the world’s greatest unmet medical needs.

“Many additional treatments may also be leveraged out of the science that lead to C-Cure discovery, and my role will be to fully develop the potential of Cardio3 BioSciences’ unique technology.”